(12)

(11) EP 2 551 266 A8

CORRECTED EUROPEAN PATENT APPLICATION

published in accordance with Art. 153(4) EPC

(15) Correction information:

Corrected version no 1 (W1 A1) Corrections, see

Bibliography INID code(s) 71

(48) Corrigendum issued on: **29.05.2013 Bulletin 2013/22**

(43) Date of publication: **30.01.2013 Bulletin 2013/05**

(21) Application number: 11758773.3

(22) Date of filing: 16.03.2011

(51) Int Cl.:

C07D 277/56 (2006.01) A61K 31/427 (2006.01) A61P 31/20 (2006.01) A61P 31/14 (2006.01)

(86) International application number: PCT/CN2011/071851

(87) International publication number: WO 2011/116663 (29.09.2011 Gazette 2011/39)

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 24.03.2010 CN 201010131636

- (71) Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 (CN)
- (72) Inventors:
 - NAN, Fajun Shanghai 201203 (CN)

• ZUO, Jianping Shanghai 201203 (CN)

 ZHANG, Yangming Shanghai 201203 (CN)

 TANG, Wei Shanghai 201203 (CN)

(74) Representative: Grünecker, Kinkeldey, Stockmair & Schwanhäusser Leopoldstrasse 4 80802 München (DE)

- (54) 2',2-DITHIAZOL NON-NUCLEOSIDE COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES AS HEPATITIS VIRUS INHIBITORS THEREOF
- (57) The present disclusure belongs to the field of pharmaceutical chemistry, and relates to a class of 2',2-bisthiazole non-nucleoside compounds of following formula I, the preparation method and the pharmaceutical composition thereof. The compounds have both the anti-HBV and anti-HCV activities and are useful in treating hepatitides B and C. Pharmacokinetic tests showed the compounds have good bioavailability.

Ĭ